
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
MMS Holdings Inc., a data-focused CRO, announced that the company has assisted Korea-based Vivozon Inc. in achieving a Fast Track Designation from the Food and Drug Administration for VVZ-149, a non-opioid painkiller. Read the full release






